Corydaline is a pharmacologically active isoquinoline alkaloid isolated from Corydalis tubers. It also has diverse biological activities. It exhibits the antiacetylcholinesterase(AChE; IC50 = 15 μM),[2] antiallergic, antinociceptive, and gastric emptying activities.
Corydaline exhibited strong nematocidal activity, showed little cytotoxicity and represents a potential treatment for Strongyloidiasis. Corydaline is nematocidal against S. ratti and S. venezuelensis third instar larvae with 50% paralysis (PC50) values of 18 and 30 μM, respectively.[3]
Corydaline exhibits gastrointestinal modulatory, antinociceptive, anti-allergic, and anti-parasitic activities. Corydaline (1 and 3 mg/kg) increases gastric emptying in rat models of apomorphine- and laparotomy-induced delayed gastric emptying.[4] Corydaline is currently in clinical trials as a potential treatment for functional dyspepsia.
In animal models, corydaline increases gastric emptying and small intestine transit speed and induces gastric relaxation.
In other animal models, corydaline inhibits chemically induced pain. Additionally, this compound may inhibit mast cell-dependent smooth muscle contraction of the aorta.
It inhibits thrombin-induced platelet aggregation in vitro (IC50 = 54.16 μg/ml).[5]